- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01871454
Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers
Effect of Pentoxifylline and Vitamin E in Preventing Radiation-induced Toxicity in the Treatment of Recurrent or New Primary NSCLC Using Stereotactic Ablative Radiotherapy in Patients Previously Treated With Thoracic Radiation
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Recruiting
- James Graham Brown Cancer Center, U of Louisville
-
Contact:
- Teresa L Roberts, RN
- Phone Number: 502-333-6934
- Email: teresa.roberts@louisville.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
3.1 Inclusion Criteria: - Eligibility Criteria
3.1.1 Age >/= 18 years
3.1.2 ECOG performance status 0-1 3.1.3 Histologically proven diagnosis of a prior thoracic malignancy treated with thoracic external beam radiotherapy with or without systemic chemotherapy
3.1.4 Pathologic or clinical diagnosis of a new or loco-regional recurrent lung malignancy. A reasonable attempt should be made to make a pathologic diagnosis of malignancy (ie. bronchoscopy, CT guided lung biopsy)
- Loco-regional is defined as recurrence within the region of the primary tumor or adjacent draining lymph node regions.
- The new lesion or loco-regional recurrence must be within or adjacent to the previously irradiated treatment volume.
3.1.5 Imaging as follows:
- CT scan of the chest with IV contrast within 8 weeks of registration
- Whole body PET scan within 8 weeks of registration
3.1.6 Pulmonary function test (PFTs), including diffusion capacity within 8 weeks of registration
3.1.7 Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential.
3.1.6 Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control
3.1.7 Patients must provide study specific informed consent prior to study entry.
Exclusion Criteria:
- 3.2 Exclusion Criteria
3.2.1. No previously reported thoracic radiotherapy
3.2.2. FEV1 <20% predicted and/or DLCO <20% predicted
3.2.2. Pregnant women or lactating women
3.2.3 Chemotherapy within 4 weeks of the initiation of SABR
3.2.4 Plans to administer systemic chemotherapy overlapping with radiotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: radiotherapy (SABR) plus pentoxifylline
standard of care radiotherapy (SABR) plus pentoxifylline and Vitamin E
|
standard of care radiation therapy
pentoxifylline
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
primary endpoint is to estimate overall treatment-related toxicity
Time Frame: 36 months-end of trial
|
36 months-end of trial
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Estimate progression free survival
Time Frame: 12 months
|
12 months
|
Estimate tumor failure
Time Frame: 12 months
|
12 months
|
estimate overall survival
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Neal E Dunlap, MD, James Graham Brown Cancer Center-U of Louisville
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Enzyme Inhibitors
- Platelet Aggregation Inhibitors
- Protective Agents
- Antioxidants
- Phosphodiesterase Inhibitors
- Free Radical Scavengers
- Radiation-Protective Agents
- Pentoxifylline
Other Study ID Numbers
- BCC-RAD-13-Pentoxifylline
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancers
-
Stanford UniversityThe American Association of Physicists in MedicineTerminatedPancreatic Cancer | Lung Cancer | Liver Cancer | Hepatobiliary Cancers | Hepatobiliary Cancers Liver | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer Small Cell Lung Cancer (SCLC) | Hepatobiliary Cancers Hepatocellular Carcinoma (Hepatoma) | Hepatobiliary Cancers Gallbladder | Hepatobiliary Cancers...United States
-
National Cancer Institute (NCI)CompletedNon-Small-Cell Lung Carcinoma | Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura | Advanced Esophageal Cancers | Primary Small Cell Lung Cancers | Pleural MesotheliomasUnited States
-
Genentech, Inc.CompletedNon-Squamous Non-Small Cell Lung Cancer, Solid CancersUnited States, Netherlands
-
Stanford UniversityTerminatedHead and Neck Cancer | Colorectal Neoplasms | Lung Cancer | Colon Cancer | Colonic Neoplasms | Head and Neck Cancers | Anal, Colon, and Rectal Cancers | Colon/Rectal Cancer | Colon/Rectal Cancer Colon Cancer | Colon/Rectal Cancer Rectal Cancer | Colon/Rectal Cancer Anal Cancer | Head and Neck Cancers Lip | Head... and other conditionsUnited States
-
Genentech, Inc.CompletedNon-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, MelanomaUnited States
-
M.D. Anderson Cancer CenterMirati Therapeutics Inc.RecruitingAdvanced Solid Tumor | Non-small Cell Lung CancersUnited States
-
Latin American Cooperative Oncology GroupJanssen, LPRecruitingMetastatic Non-small Cell Lung CancersBrazil
-
Prelude TherapeuticsRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancers | SMARCA4 Gene MutationUnited States, France, Spain, Singapore, Netherlands
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaRecruitingNon-small Cell Lung Cancer | Metastasis From Other CancersCanada
-
Cancer Research and Biostatistics Clinical Trials...Washington University School of Medicine; Lucille P. Markey Cancer Center at...UnknownSmall Cell Lung Carcinoma | Non Small Cell Lung Carcinoma | Irinotecan Sensitive CancersUnited States
Clinical Trials on stereotactic ablative radiotherapy (SABR)
-
Stanford UniversityVarian, a Siemens Healthineers CompanyActive, not recruitingEmphysemaUnited States
-
University of Texas Southwestern Medical CenterWithdrawnTachycardia, VentricularUnited States
-
University Medical Center GroningenCompleted
-
University of Texas Southwestern Medical CenterActive, not recruitingProstate CancerUnited States
-
Cancer Research AntwerpCompleted
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
Mayo ClinicCompleted
-
European Institute of OncologyAssociazione Italiana per la Ricerca sul CancroRecruiting
-
European Organisation for Research and Treatment...UnknownNon-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIGermany, Belgium, United Kingdom, Switzerland
-
Fudan UniversityRecruiting